Showing results (181-190 of 225) with videos related to

Sort By:
Pageof 23
Rheumatology Advances in Practice|June 19, 2024
Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis CohortBrook Hadwen, Saverio Stranges, Janet E Pope, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Arthritis and Rheumatism|November 30, 2006
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian populationWilliam G Newman, Qing Zhang, Xiangdong Liu, et al.
Arthritis Care & Research|December 2, 2017
Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort StudyElizabeth Schulman, Susan J Bartlett, Orit Schieir, et al.
BMJ Open|July 1, 2016
Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative studyRebecca J Stack, Michaela Stoffer, Mathias Englbrecht, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Arthritis Care & Research|May 22, 2019
Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective CohortCristiano S Moura, Orit Schieir, Marie-France Valois, et al.
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
Annals of the Rheumatic Diseases|February 14, 2014
The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'Lilian H D van Tuyl, Sarah Hewlett, Martina Sadlonova, et al.
Clinical Therapeutics|July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Pageof 23